Darwin Discovery Limited

Ucb S.a.

Celltech R&d Limited

Ucb Pharma, S.a.

Darwin Molecular Corporation

Ucb Manufacturing, Inc.

Mary E Brunkow

Bryan W Paeper

Brian Robert Kovacevich

Jeffrey Van Ness

John Thomas Mulligan

David J Galas

David Guenther Winkler

Fred Ramsdell

Kathryn Hjerrild

Eric W Jeffery

Sean Proll

Karen Staehling-Hampton

David J Winkler

Patrick R Charmley

Andreas Gerardus Uitterlinden

Brian W Paeper

Roli Khattri

Kathryn A Hjerrild

A novel class or family of TGF-&#x3b2; binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

Compositions and methods for increasing bone mineralization

Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.

The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.

Method for detecting an individual who is afflicted with or a carrier for Van Buchem's disease

Compositions and methods are provided for determining in a subject a risk for having, or presence of, altered bone mineral density such as osteoporosis or osteopenia or other conditions characterized by decreased or increased bone density. Specifically, the invention relates to determination of a sclerostin gene region nucleotide polymorphism (SRP) in DNA of the sclerostin gene region of human chromosome 17. In certain embodiments, SRPs that indicate an increased risk for altered bone mineral density occur as gender-associated polymorphisms. Isolated polynucleotides comprising representative SRPs are also provided.

[object Object]

Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF-&#x3b2; binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.

Antibodies associated with alterations in bone density

Nucleic acids relating to human TGF-&#x3b2; binding proteins are disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

Isolated nucleic acid molecules are provided which encode Fkh, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Also provided are pharmaceutical compounds and methods of identifying such compounds that can modulate the immune system. In addition are provided methods for identifying proteins regulated by Scurfin (Fkh) and proteins that induce or inhibit Scurfin or Foxp3 expression.

Method for regulating immune function using the FOXP3 protein

Isolated nucleic acid molecules are provided which encode Fkh, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof), numerous molecules may be identified which modulate the immune system.

Identification of the gene causing the mouse scurfy phenotype and its human ortholog

Antibodies to a novel family of TGF-&#x3b2; binding proteins are disclosed, for use in methods of altering bone density and bone mineralization, which methods are applicable to the treatment of diseases including osteopenia and osteoporosis.

Methods for modulating bone mineralization

Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF-&bgr; binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.

Isolated nucleic acid molecules are provided which encode Fkh , as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof), numerous molecules may be identified which modulate the immune system.

Growing community of inventors

Seattle, WA, United States of America

Mary E Brunkow